Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its ...

Early in the progression of Alzheimer's and other neurodegenerative diseases, DNA inside neurons starts showing signs of ...

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

UCSF just launched one of the first trials to test whether attacking two proteins simultaneously can slow or stop Alzheimer's ...

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, ...

Stay informed with the latest news and expert insights on Alzheimer’s disease here. In our efforts to keep our brains healthy, how do we know what is working? Helen Thomson explores a new generation o ...

Many Alzheimer's medications slow the disease, but this non-drug treatment helped patients improve.

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Pat ...

Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager ...

Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...

Playing a mental speed-training game seems to help the brain clear a protein linked to Alzheimer’s disease in men, but may ...

The Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN), a global collaboration of academic researchers, pharmaceutical companies, and philanthropic ...